Monotherapy with LF 15-0195, an analogue of 15-deoxyspergualin, significantly prolongs renal allograft survival in monkeys

Transplantation

Volumn 75, Issue 8, 2003, Pages 1166-1171

  Yang, Hongji ^a   Chen, Gang ^a   Kanai, Nobuyuki ^a   Shum, Jeffrey ^a   Garcia, Bertha ^a,b   Huang, Xuyan ^a,c   Min, Weiping ^a,b,c,d   Luo, Yigang ^b   Dutartre, Patrick ^e   Zhong, Robert ^a,b,c,d  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

^c ROBARTS RESEARCH INSTITUTE   (Canada)

^d LAWSON HEALTH RESEARCH INSTITUTE   (Canada)

^e Laboratoires Fournier SA   (France)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXYSPERGUALIN; HEMOGLOBIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOSUPPRESSIVE AGENT; LF 15 0195; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AUTOPSY; COLON; CONFERENCE PAPER; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENCY; GRAFT SURVIVAL; HEART; HEMOGLOBIN DETERMINATION; HISTOPATHOLOGY; IMMUNOGLOBULIN BLOOD LEVEL; INTESTINE; KIDNEY ALLOGRAFT; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; LIVER; LYMPHOCYTE; MONKEY; MONOTHERAPY; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; SPLEEN; STOMACH; SURVIVAL; THROMBOCYTE; TREATMENT OUTCOME;

ANIMALS; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; GRAFT REJECTION; GRAFT SURVIVAL; GUANIDINES; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY TRANSPLANTATION; LYMPHOCYTE COUNT; MACACA FASCICULARIS; OSMOLAR CONCENTRATION; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0037469068     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000062841.89728.CF     Document Type: Conference Paper

References (22)

1. Toma H, Tanabe K, Tokumoto T. Long-term outcome of ABO-incompatible renal transplantation. Urol Clin North Am 2001; 28: 769.
2. Kupiec-Weglinski JW. Graft rejection in sensitized recipients. Ann Transplant 1996; 1: 34.
3. Iwasawa H, Kondo S, Ikeda D, et al. Synthesis of (-)-15-deoxyspergualin and (-)-spergualin-15-phosphate. J Antibiot (Tokyo) 1982; 35: 1665.
4. Kaufman DB. 15-Deoxyspergualin in experimental transplant models: A review. Transplant Proc 1996; 28: 868.
5. Lebreton L, Annat J, Derrepas P, et al. Structure-immunosuppressive activity relationships of new analogues of 15-deoxyspergualin. 1. Structural modifications of the hydroxyglycine moiety. J Med Chem 1999; 42: 277.
6. + suppressor cells. Transplantation 1996; 62: 1543.
7. Zhou D, O'Brien C, Garcia B, et al. LF 15-0195, a novel immunosuppressive agent, prevents rejection and induces tolerance in a mouse cardiac allograft model. Am J Transplant 2001; l(suppl 1): 437.
8. Knapp LA, Lehmann E, Hennes L, et al. High-resolution HLA-DRB typing using denaturing gradient gel electrophoresis and direct sequencing. Tissue Antigens 1997; 50: 170.
9. Davis ML, Austin C, Messmer BL, et al. IFCC-standardized pediatric reference intervals for 10 serum proteins using the Beckman Array 360 system. Clin Biochem 1996; 29: 489.
10. Takeuchi T, Iinuma H, Kunimoto S, et al. A new antitumor antibiotic, spergualin: Isolation and antitumor activity. J Antibiot (Tokyo) 1981; 34: 1619.
11. Nadler SG, Tepper MA, Schacter B, et al. Interaction of the immunosuppressant deoxyspergualin with a member of the Hsp70 family of heat shock proteins. Science 1992; 258: 484.
12. Komesli S, Dumas C, Dutartre P. Analysis of in vivo immunosuppressive and in vitro interaction with constitutive heat shock protein 70 activity of LF08-0299 (Tresperimus) and analogues. Int J Immunopharmacol 1999; 21: 349.
13. Morikawa K, Oseko F, Morikawa S. The suppressive effect of deoxyspergualin on the differentiation of human B lymphocytes maturing into immunoglobulin-producing cells. Transplantation 1992; 54: 526.
14. Leventhal JR, Platt JL, Flores HC, et al. Inhibition of natural antibody synthesis by cyclophosphamide or 15-deoxyspergualin fails to prevent xenograft rejection in the guinea pig-to-rat model. Transplant Proc 1992; 24: 551.
15. Reichenspurner H, Human PA, Rose AG, et al. Effect of pharmacologic immunosuppression on donor heart survival in a closely related nonhuman primate xenograft model. Transplant Proc 1990; 22: 1086.
16. Gannedahl G, Ohlman S, Persson U, et al. Rejection associated with early appearance of donor-reactive antibodies after kidney transplantation treated with plasmapheresis and administration of 15-deoxyspergualin: A report of two cases. Transplant Int 1992; 5: 189.
17. Takahashi K, Tanabe K, Ooba S, et al. Prophylactic use of a new immunosuppressive agent, deoxyspergualin, in patients with kidney transplantation from ABO-incompatible or preformed antibody-positive donors. Transplant Proc 1991; 23: 1078.
18. Amemiya A, Dohi K, Otsubo O, et al. Markedly enhanced therapeutic effect of deoxyspergualin on acute rejection when combined with methylprednisolone in kidney recipients. Transplant Proc 1991; 23: 1087.
19. Crespo M, Pascual M, Tolkoff-Rubin N, et al. Acute humoral rejection in renal allograft recipients. I. Incidence, serology and clinical characteristics. Transplantation 2001; 71: 652.
20. Bohmig GA, Regele H, Exner M, et al. C4d-positive acute humoral renal allograft rejection: Effective treatment by immunoadsorption. J Am Soc Nephrol 2001; 12: 2482.
21. Fukao K, Iwasaki H, Yuzawa K, et al. Immunosuppressive effect and toxicity of 15-deoxyspergualin in cynomolgus monkey. Transplant Proc 1991; 23: 556.
22. Sebille F, Guillet M, Brouard S, et al. T-cell-mediated rejection of vascularized xenografts in the absence of induced anti-donor antibody response. Am J Transplant 2001; 1: 21.